Drugs Currently Undergoing Preclinical or Clinical Trials for the Treatment of Overactive Bladder: A Review

IF 1.6 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Current Therapeutic Research-clinical and Experimental Pub Date : 2022-01-01 DOI:10.1016/j.curtheres.2022.100669

Silvia Joseph MBBS, Steffi A. Maria MD, Jacob Peedicayil MD

{"title":"Drugs Currently Undergoing Preclinical or Clinical Trials for the Treatment of Overactive Bladder: A Review","authors":"Silvia Joseph MBBS, Steffi A. Maria MD, Jacob Peedicayil MD","doi":"10.1016/j.curtheres.2022.100669","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Overactive bladder (OAB) is a common clinical condition for which current drug treatment comprises drugs blocking the cholinergic nerve supply, or augmenting the adrenergic nerve supply, to the detrusor muscle of the urinary bladder. Current treatments have drawbacks, including lack of efficacy and the development of adverse effects in some patients. Hence, new and better drugs for treating OAB will be clinically useful.</p></div><div><h3>Objective</h3><p>This review is meant to provide information on drugs currently undergoing preclinical or clinical trials for the treatment of OAB published in journal articles or elsewhere.</p></div><div><h3>Methods</h3><p>The cited articles were retrieved from PubMed and Google Scholar from January 1, 1990, to December 31, 2021. The search terms used were <em>contraction</em> or <em>contractility, detrusor, inhibition, isolated</em> or <em>in vitro, in vivo, overactive bladder</em>, and <em>relaxant effect</em> or <em>relaxation</em>.</p></div><div><h3>Results</h3><p>There are 4 classes of new drugs under various stages of development for the treatment of OAB. These are drugs acting on the autonomic nerve supply to the detrusor muscle of the urinary bladder that include the anticholinergics tarafenacin and afacifenacin and the β<sub>3</sub> adrenoceptor agonists solabegron and ritobegron; drugs acting on ion channels in the detrusor muscle (eg, potassium channel openers and calcium channel blockers), drugs acting on cellular enzymes like phosphodiesterase-5 inhibitors and Rho kinase inhibitors, and drugs acting on miscellaneous targets (eg, pregabalin and trimetazidine).</p></div><div><h3>Conclusions</h3><p>Drugs currently used to treat OAB target only the cholinergic and adrenergic cellular signalling pathways. There are many other drugs under trial targeting other cellular pathways that may be useful for treating OAB. Their approval for clinical use might improve the treatment of patients with OAB. (<em>Curr Ther Res Clin Exp</em>. 2022; 83:XXX–XXX)</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"96 ","pages":"Article 100669"},"PeriodicalIF":1.6000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0011393X2200008X/pdfft?md5=0dd817fbf247b933f733ccead9a27768&pid=1-s2.0-S0011393X2200008X-main.pdf","citationCount":"12","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Therapeutic Research-clinical and Experimental","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0011393X2200008X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 12

Abstract

Background

Overactive bladder (OAB) is a common clinical condition for which current drug treatment comprises drugs blocking the cholinergic nerve supply, or augmenting the adrenergic nerve supply, to the detrusor muscle of the urinary bladder. Current treatments have drawbacks, including lack of efficacy and the development of adverse effects in some patients. Hence, new and better drugs for treating OAB will be clinically useful.

Objective

This review is meant to provide information on drugs currently undergoing preclinical or clinical trials for the treatment of OAB published in journal articles or elsewhere.

Methods

The cited articles were retrieved from PubMed and Google Scholar from January 1, 1990, to December 31, 2021. The search terms used were contraction or contractility, detrusor, inhibition, isolated or in vitro, in vivo, overactive bladder, and relaxant effect or relaxation.

Results

There are 4 classes of new drugs under various stages of development for the treatment of OAB. These are drugs acting on the autonomic nerve supply to the detrusor muscle of the urinary bladder that include the anticholinergics tarafenacin and afacifenacin and the β₃ adrenoceptor agonists solabegron and ritobegron; drugs acting on ion channels in the detrusor muscle (eg, potassium channel openers and calcium channel blockers), drugs acting on cellular enzymes like phosphodiesterase-5 inhibitors and Rho kinase inhibitors, and drugs acting on miscellaneous targets (eg, pregabalin and trimetazidine).

Conclusions

Drugs currently used to treat OAB target only the cholinergic and adrenergic cellular signalling pathways. There are many other drugs under trial targeting other cellular pathways that may be useful for treating OAB. Their approval for clinical use might improve the treatment of patients with OAB. (Curr Ther Res Clin Exp. 2022; 83:XXX–XXX)

查看原文本刊更多论文

目前正在进行治疗膀胱过动症的临床前或临床试验的药物:综述

膀胱过度活动(OAB)是一种常见的临床疾病，目前的药物治疗包括阻断膀胱逼尿肌的胆碱能神经供应或增加肾上腺素能神经供应的药物。目前的治疗方法有缺点，包括缺乏疗效和在一些患者中出现不良反应。因此，新的和更好的药物治疗OAB将是临床有用的。目的:本综述旨在提供目前正在进行临床前或临床试验的治疗OAB的药物在期刊文章或其他地方发表的信息。方法检索1990年1月1日至2021年12月31日的PubMed和b谷歌Scholar论文。使用的搜索词是收缩或收缩性，逼尿肌，抑制，分离或体外，体内，膀胱过度活跃，松弛作用或松弛。结果治疗OAB的新药有4类，处于不同的开发阶段。这些药物作用于膀胱逼尿肌的自主神经包括抗胆碱能药物塔拉非那新和阿非那新β3肾上腺素受体激动剂索拉贝隆和利托贝隆;作用于逼尿肌离子通道的药物(如钾通道开放剂和钙通道阻滞剂)，作用于细胞酶如磷酸二酯酶-5抑制剂和Rho激酶抑制剂的药物，以及作用于其他靶点的药物(如普瑞巴林和曲美他嗪)。结论目前用于治疗OAB的药物仅针对胆碱能和肾上腺素能细胞信号通路。还有许多其他药物正在试验中，针对其他细胞途径，可能对治疗OAB有用。它们的临床应用可能会改善OAB患者的治疗。(中国临床医学杂志，2022;83: XXX-XXX)

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Therapeutic Research-clinical and Experimental 医学-药学

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： We also encourage the submission of manuscripts presenting preclinical and very preliminary research that may stimulate further investigation of potentially relevant findings, as well as in-depth review articles on specific therapies or disease states, and applied health delivery or pharmacoeconomics. CTR encourages and supports the submission of manuscripts describing: • Interventions designed to understand or improve human health, disease treatment or disease prevention; • Studies that focus on problems that are uncommon in resource-rich countries; • Research that is "under-published" because of limited access to monetary resources such as English language support and Open Access fees (CTR offers deeply discounted English language editing); • Republication of articles previously published in non-English journals (eg, evidence-based guidelines) which could be useful if translated into English; • Preclinical and clinical product development studies that are not pursued for further investigation based upon early phase results.